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A single-nucleotide polymorphism (SNP) in the promoter region
of MDM2, SNP 309, is associated with hepatocellular carcinoma
(HCC) in patients with chronic hepatitis C virus infection. The
effect of p53 codon 72 polymorphism Arg72Pro on HCC risk
remains inconsistent. This study evaluated the association of
MDM2 and p53 polymorphisms with the presence and early onset
of HCC in Korean patients with chronic hepatitis B virus (HBV)
infection. In total, 583 consecutive patients with chronic HBV
infection were classified according to the presence (n 5 287) or
absence (n 5 296) of HCC. The MDM2 SNP 309 and p53 Arg72-
Pro were genotyped using restriction fragment length polymor-
phism method. The MDM2 G/G and p53 Pro/Pro genotypes were
more frequent in HCC group than in non-HCC group (P < 0.001
and P 5 0.004, respectively). Multivariate analysis for the pres-
ence of HCC revealed that the odds ratio (OR) for MDM2 G/G
over T/T was 4.89 (P < 0.001) and that of p53 Pro/Pro over Arg/
Arg was 3.03 (P 5 0.006). Combined MDM2 G/G and p53 Pro/
Pro had a synergistic effect on HCC risk, with an OR of 20.78
(P < 0.001). The mean age of tumor onset in patients withMDM2
G/G genotype was 50.9 years compared with 55.1 with T/T geno-
type (P 5 0.018) and that with p53 Pro/Pro was 49.7 years com-
pared with 52.9 with Arg/Arg (P 5 0.040). Thus,MDM2 SNP 309
and p53 Arg72Pro are associated with the early development of
HCC in Korean patients with chronic HBV infection.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common tumor
worldwide and accounts for .500 000 deaths each year (1,2). The
incidence of HCC is not uniform throughout the world, but varies
according to the prevalence of the underlying liver disease (3). It
has been recognized that most important risk factor for the develop-
ment of HCC is cirrhosis (4). Chronic infections with hepatitis B virus
(HBV) and hepatitis C virus (HCV) are the most frequent causes of
cirrhosis worldwide. In Asia, chronic HBV infection is the most im-
portant factor in the etiology of HCC (5,6). Virus factors such as HBV
genotype, viral load and mutations in the basal core promoter (BCP)
and the precore (PC) region of HBV have been associated with HCC
development (5,7–9). Additional factors, such as age, gender, concur-
rent alcohol use and a-fetoprotein (AFP) levels, also contribute to the
development of HCC (10). Finally, various genetic factors appear to
affect the outcome of HBV infections (11–15).
MDM2 is an important negative regulator of p53 that forms a neg-
ative autoregulatory feedback loop with p53 by binding to its N-
terminal transactivation domain, inhibiting its transcriptional activity
(16). Recently, the 309T.G polymorphism [single-nucleotide polymor-
phism (SNP) 309, rs2279744], located in the intronic p53-responsive
promoter of the MDM2 gene, was found to increase Sp1 transcription
factor binding and subsequent MDM2 protein levels (17). This in-
crease in MDM2 results in the direct inhibition of p53 transcriptional
activity, enabling the damaged cells to escape the cell-cycle check-
point control and become carcinogenic (18). MDM2 SNP 309 is
associated with the early onset of some malignancies, suggesting that
it has a strong effect on tumorigenesis in humans (19). Furthermore,
Dharel et al. (20) reported that MDM2 SNP 309 was associated with
HCC in patients with chronic HCV infection.
Because the loss of p53 function plays a critical role in multistage
hepatocarcinogenesis, the p53 gene is a good candidate for modulat-
ing HCC risk (21). Genetic polymorphisms also exist in the p53 gene,
including the functionally significant 215G.C polymorphism at co-
don 72 (Arg72Pro, rs1042522) (22). Dumont et al. (23) reported that
the Arg72 variant induced apoptosis more effectively than the Pro72
variant, which may influence cancer risk. The Pro72 variant has been
identified as a risk factor for some malignancies, but the relationship
between this polymorphism and the outcome of HBV infection has
not yet been firmly established (11,24,25).
Zhang et al. (18) tested the gene–gene interactions between MDM2
SNP 309 and p53 Arg72Pro in lung cancer and showed that these two
polymorphisms increased the risk of lung cancer in a supermultiplica-
tive manner. The combined influence of these two polymorphisms
was also tested in hereditary non-polyposis colorectal cancer, and
the results indicated that MDM2 SNP 309, alone or in combination
with p53 Arg72Pro, did not influence the age at diagnosis of non-
polyposis colorectal cancer patients (26).
To clarify the association of the MDM2 SNP 309 and p53 Arg72-
Pro, alone or in combination, with the risk of HCC in patients with
chronic HBV infection, we analyzed the association of these SNPs
with the presence of HCC and age at the time of diagnosis.
Patients and methods
Clinical data
Five hundred and eighty-three consecutive patients with chronic HBV infection
who visited Severance Hospital between December 2004 and October 2006 were
enrolled. All patients were ethnic Koreans and were stratified into two groups
according to the presence (n 5 287) or absence (n 5 296) of HCC. Only newly
diagnosed HCC patients were included; patients with a prior history of HCC or
other cancers were excluded. All patients tested positive twice for the hepatitis B
surface antigen (Abbott, Wiesbaden, Germany) over a 6-month interval and
tested negative for the HCV antibody (Green Cross Medical Science Corp.,
Yongin-shi, Korea). This study was approved by the Institutional Review Board
of the Severance Hospital, and written informed consent was obtained from all
study subjects. HCC was diagnosed either histologically or by typical HCC
imaging patterns, using angiography, computed tomography and/or magnetic
resonance imaging, sometimes combined with serum AFP analysis. Liver cir-
rhosis was determined by histology, imaging or clinical indications, such as
esophageal varices or ascites. Age, gender and serum AFP were recorded.
Heavy alcohol intake was defined as ethanol intake 80 g/day for .10 years.
SNP analysis
Genomic DNA was extracted from a 200 ll peripheral blood sample using
a QIAamp blood kit (Qiagen, Chatsworth, CA) according to the manufacturer’s
instructions. For MDM2 genotyping, DNA was amplified by polymerase chain
reaction (PCR) using the following primers: 5#-GATTTCGGACGGC-
TCTCGCGGC-3# (sense) and 5#-CATCCGGACCTCCCGCGCTG-3# (anti-
sense). In the antisense primer, a PstI restriction site was created by
Abbreviations: AFP, a-fetoprotein; BCP, basal core promoter; CI, confidence
interval; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepa-
titis C virus; HWE, Hardy–Weinberg equilibrium; OR, odds ratio; PC, precore;
PCR, polymerase chain reaction; SNP, single-nucleotide polymorphism.
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introducing a mismatched A in the place of a G at a site 2 bp from the poly-
morphic site. The 121 bp PCR product was then digested overnight with 5 U
PstI (New England BioLabs, Beverly, MA). The DNA fragments were sepa-
rated by electrophoresis on 3% NuSieve agarose gels. The wild-type T allele
produced a single 121 bp fragment, and the polymorphic G allele produced
fragments of 104 and 17 bp. The p53 codon 72 was genotyped using the
primers 5#-TTGCCGTCCCAAGCAATGGATGA-3# (sense) and 5#-TCTGG-
GAAGGGACAGAAGATGAC-3# (antisense). The 199 bp PCR product was
digested with AccII (New England BioLabs) for 2 h at 37C. AccII digestion of
the amplified fragment identified two alleles: the Arg allele produced 113 and
86 bp fragments and the Pro allele produced a 199 bp fragment.
Quantification of HBV DNA
HBV DNA was measured using hc2 HBV DNA Test (Digene, Gaithersburg,
MD) as described in the manufacturer’s protocol. The minimum quantifiable
concentration was 1.4  105 copies/ml. HBV DNA1.4  105 copies/ml was
considered HBV DNA positive in this study. Samples with undetectable HBV
DNA, which were considered to have HBV DNA levels,1.4  105 copies/ml,
were defined as HBV DNA negative.
HBV genotyping
HBV genotypes were analyzed by restriction fragment mass polymorphism
using matrix-assisted laser desorption/ionization time of flight mass spectrom-
etry as described previously (27). The assay was based on the mass measure-
ment of oligonucleotides having genotypic variations of the S gene.
Sequencing of BCP and PC regions of HBV
Sequencing of BCP and PC regions of HBV genome was performed by am-
plification of a nucleotide using nested PCR and direct sequencing of the
purified PCR fragments. The primers were designed to flank nucleotide posi-
tions 1660–1919 of the BCP and PC regions of HBV DNA. External primers
were 5#-CATAAGATGGACTCTTGGACT-3# (sense, positions 1653–1672)
and 5#-GGAAAGAAATCAGAAGGCA-3# (antisense, positions 1974–1956).
Internal primers were 5#-GGACTCTTGGACTCTCTCAGCAA-3# (sense,
positions 1660–1680) and 5#-TCCACAGAAGCTCCAAATTTCTTT-3# (anti-
sense, positions 1941–1919). The sequencing of target PCR fragments was
determined using the primers of the second round PCR with a 3100 Automatic
Sequencer (Applied Biosystems, Foster City, CA). A dual mutation in BCP
region involving an A to T substitution at nucleotide 1762 and a G to A sub-
stitution at nucleotide 1764 were examined. Also, a mutation in PC region
involving a G to A substitution at nucleotide 1896 was identified.
Statistical analysis
Statistical analysis including Hardy–Weinberg equilibrium (HWE) was per-
formed using Statistical Analysis System Genetics 9.13 (SAS Institute, Cary,
NC). The characteristics of HCC and non-HCC patients were compared using
the two-sample t-test for continuous variables and the v2 test for categorical
variables. The v2 test was used to compare genotype frequencies among sub-
jects. The association between HCC and the genotypes was estimated based on
an odds ratio (OR) and a 95% confidence interval (CI) using a multivariate
logistic regression model. The ages at the diagnosis of HCC between geno-
types were compared using analysis of variance with least significance differ-
ence method. For all tests, P , 0.05 was considered significant.
Results
The characteristics of the study population are presented in Table I.
There were no significant differences of gender, HBV DNA positive
and PC 1896 between HCC and non-HCC patients. However, all the
other variables including age, cirrhosis, heavy alcohol intake, AFP
20 ng/ml, HBV genotype C and BCP 1762/1764 were significantly
different between two groups. As for HBV genotype, genotype non-C
patients were all proved to be genotype A.
Tables II and III present the genotype distributions of MDM2 SNP
309 and p53 Arg72Pro, respectively. In the non-HCC group, the
P-values of HWE for the genotype frequencies of MDM2 SNP 309
and p53 Arg72Pro were 0.063 and 0.978, respectively. Also, P-value
of HWE for MDM2 SNP 309 in HCC group was 0.233. However, the
genotype frequencies of p53 Arg72Pro in HCC group deviated sig-
nificantly from those expected under the HWE (P , 0.001).
In the HCC group, the proportions of the T/T, T/G and G/G geno-
types were 15.7, 43.5 and 40.8%, respectively, which were signifi-
cantly different from those observed in the non-HCC group
(P , 0.001). In comparison with the T/T genotype, the crude ORs
Table I. Characteristics of the study population
Variable HCC
(N 5 287), n (%)
Non-HCC
(N 5 296), n (%)
P-value
Gender
Male 228 (79.4) 236 (79.7)
0.931
Female 59 (20.6) 60 (20.3)
Age (years)a 52.3 ± 9.5 36.7 ± 11.9 ,0.001
Cirrhosis 210 (73.2) 48 (16.2) ,0.001
Heavy alcohol intake 52 (18.1) 24 (8.1) ,0.001
HBV DNA positive 140 (48.8) 130 (43.9) 0.239
AFP 20 ng/ml 179 (62.4) 27 (9.1) ,0.001
HBV genotype C 284 (99.0) 284 (95.9) 0.022
BCP 1762/1764
Wild-type 103 (35.9) 131 (44.3)
0.039
T1762/A1764 mutant 184 (64.1) 165 (55.7)
PC 1896
Wild-type 218 (76.0) 234 (79.1)
0.371
A1896 mutant 69 (24.0) 62 (20.9)
aAge (years) is shown as mean ± SD, calculated by a two-sample t-test.
Table II. Genotype frequencies of MDM2 SNP 309
Polymorphism HCC,
n (%)
Non-HCC,
n (%)
Crude OR
(95% CI) for
HCC presence
Adjusted OR
(95% CI) for
HCC presencea
Genotype
T/T 45 (15.7) 83 (28.0) 1.00 1.00
T/G 125 (43.5) 132 (44.6) 1.75 (1.13–2.71) 3.45 (1.71–6.94)
G/G 117 (40.8) 81 (27.4) 2.67 (1.68–4.22) 5.61 (2.67–11.74)
Recessive
model
T/T þ T/G 170 (59.2) 215 (72.6) 1.00 1.00
G/G 117 (40.8) 81 (27.4) 1.83 (1.29–2.59) 2.46 (1.42–4.27)
Dominant
model
T/T 45 (15.7) 83 (28.0) 1.00 1.00
T/G þ G/G 242 (84.3) 213 (72.0) 2.10 (1.40–3.15) 4.27 (2.23–8.20)
aAdjusted for all variables listed in Table I.
P , 0.05.
Table III. Genotype frequencies of p53 Arg72Pro
Polymorphism HCC,
n (%)
Non-HCC,
n (%)
Crude OR
(95% CI) for
HCC presence
Adjusted OR
(95% CI) for
HCC presencea
Genotype
Arg/Arg 110 (38.3) 124 (41.9) 1.00 1.00
Arg/Pro 111 (38.7) 135 (45.6) 0.93 (0.65–1.33) 1.08 (0.61–1.89)
Pro/Pro 66 (23.0) 37 (12.5) 2.01 (1.25–3.24) 3.73 (1.73–8.02)
Recessive model
Arg/Arg þ
Arg/Pro
221 (77.0) 259 (87.5) 1.00 1.00
Pro/Pro 66 (23.0) 37 (12.5) 2.09 (1.35–3.25) 3.59 (1.77–7.31)
Dominant model
Arg/Arg 110 (38.3) 124 (41.9) 1.00 1.00
Arg/Pro þ
Pro/Pro
177 (61.7) 172 (58.1) 1.16 (0.83–1.62) 1.53 (0.91–2.57)
aAdjusted for all variables listed in Table I.
P , 0.05.
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(95% CI) for the presence of HCC were 1.75 (1.13–2.71; P 5 0.012)
for the T/G genotype and 2.67 (1.68–4.22; P , 0.001) for the G/G
genotype. The ORs (95% CI), which were adjusted for all the varia-
bles listed in Table I, were 3.45 (1.71–6.94; P 5 0.001) for T/G
genotype and 5.61 (2.67–11.74; P , 0.001) for G/G genotype. Sub-
jects carrying the G/G genotype had an elevated adjusted OR (95%
CI) of 2.46 (1.42–4.27; P 5 0.001) as compared with T/T or T/G
carriers. The heterozygous or homozygous variant forms (T/G or G/G)
had an adjusted OR (95% CI) of 4.27 (2.23–8.20; P , 0.001) as
compared with the homozygous T/T genotype (Table II).
The genotype frequencies of p53 Arg72Pro in HCC and non-HCC
patients are presented in Table III, and a significant difference in
genotype distribution was observed (P 5 0.004). In contrast to the
Arg/Arg genotype, the Pro/Pro genotype increased the risk of HCC
with a crude OR (95% CI) of 2.01 (1.25–3.24; P 5 0.004) and an
adjusted OR (95% CI) of 3.73 (1.73–8.02; P 5 0.001). In addition,
individuals with the Pro/Pro genotype had an elevated adjusted OR
(95% CI) of 3.59 (1.77–7.31; P , 0.001) as compared with those
with the Arg/Arg or Arg/Pro genotype.
Table IV presents the ORs (95% CI) for these HCC risk factors after
multivariate logistic regression. In comparison with the reference T/T
genotype of MDM2 SNP 309, the ORs (95% CI) for T/G and G/G
were 3.19 (1.57–6.48) and 4.89 (2.30–10.41), respectively. The Pro/
Pro genotype of p53 Arg72Pro caused a 3-fold increase in risk as
compared with the Arg/Arg genotype (OR 5 3.03, 95% CI 5
1.38–6.63). However, the heterozygous Arg/Pro genotype did not in-
crease HCC risk.
Statistical gene–gene interactions between the MDM2 and p53
polymorphisms were also examined (Table V). Crude and adjusted
ORs (95% CI) for the presence of HCC were obtained by logistic
regression. The presence of both MDM2 G/G and p53 Pro/Pro was
associated with a higher risk of HCC (adjusted OR 5 20.78, 95%
CI5 5.25–82.36). The combination of T/G and Arg/Pro, T/G and Pro/
Pro and G/G and Arg/Arg also increased the risk of HCC after ad-
justment for all variables listed in Table I.
The role of MDM2 SNP 309 and p53 Arg72Pro in HCC develop-
ment was analyzed via analysis of variance with least significance
difference method (Table VI). The mean ages of tumor diagnosis
for the MDM2 SNP 309 T/T, T/G and G/G genotypes were 55.1,
53.4 and 50.9 years, respectively. In comparison with the T/T geno-
type, a significant acceleration in the development of HCC was ap-
parent in patients with the G/G genotype (P 5 0.013).
The same analysis was applied to p53 Arg72Pro. The mean ages of
tumor diagnosis for the Arg/Arg, Arg/Pro and Pro/Pro genotypes were
52.9, 54.2 and 49.7 years, respectively. Significant early onset of HCC
was noted in patients with the Pro/Pro genotype as compared with
Arg/Arg (P 5 0.028) genotype.
Finally, the same analysis was applied to the combinations of the
MDM2 and p53 genotypes. Significant early onset of HCC was noted
in subjects with both the MDM2 G/G and p53 Pro/Pro genotypes
compared with those with T/T and Arg/Arg genotype (mean age 5
48.5, P 5 0.001). Also, subjects with G/G and Arg/Arg genotype
revealed significant early onset of HCC compared with those with
T/T and Arg/Arg genotype. In these subjects, the mean age of tumor
diagnosis was 46.7 years.
Discussion
This study demonstrated an association between genetic polymor-
phisms in MDM2 and/or p53 and the development of HCC in patients
with HBV infection.
MDM2 is an E3 ubiquitin ligase that suppresses the activity of p53
through both ubiquitinization and direct protein binding (28). MDM2
SNP 309, which is a T-to-G substitution at position 309 in the first
intron of the MDM2 gene, results in higher levels of MDM2 messen-
ger RNA and protein (29). Increased MDM2 levels inhibit p53, which
enables damaged cells to escape the cell-cycle checkpoint and be-
come carcinogenic (18). Previous studies have investigated the asso-
ciation between MDM2 SNP 309 and various malignancies, including
soft tissue sarcoma, lung cancer, esophageal squamous cell carci-
noma, colorectal cancer, head and neck squamous cell carcinoma,
breast cancer, gastric carcinoma and Li–Fraumeni syndrome
(16–19,29–36), but the results of these studies were inconsistent.
Dharel et al. (20) reported that MDM2 SNP 309 was associated with
Table IV. Multivariate analysis of risk factors for the presence of HCC
Risk factor Status OR (95% CI) P-value
Gender Female 1.00
Male 1.58 (0.81–3.07) 0.181
Age (years) 40 1.00
.40 11.19 (5.76–21.75) ,0.001
Cirrhosis Absent 1.00
Present 8.61 (4.98–14.87) ,0.001
Heavy alcohol intake Absent 1.00
Present 1.45 (0.66–3.15) 0.355
HBV DNA Negative 1.00
Positive 0.74 (0.42–1.32) 0.307
AFP (ng/ml) ,20 1.00
20 26.47 (13.18–53.19) ,0.001
HBV genotype A 1.00
C 1.78 (0.26–4.27) 0.554
BCP 1762/1764 Wild-type 1.00
T1762/A1764 2.32 (1.26–4.27) 0.007
PC 1896 Wild-type 1.00
A1896 0.69 (0.35–1.37) 0.285
MDM2 SNP 309 T/T 1.00
T/G 3.19 (1.57–6.48) 0.001
G/G 4.89 (2.30–10.41) ,0.001
p53 Arg72Pro Arg/Arg 1.00
Arg/Pro 1.10 (0.62–1.97) 0.740
Pro/Pro 3.03 (1.38–6.63) 0.006
Table V. Risk of HCC for combinations of MDM2 and p53 genotypes
MDM2 SNP 309 p53 Arg72Pro HCC, n (%) Non-HCC, n (%) Crude OR (95% CI) Adjusted OR (95% CI)a
T/T Arg/Arg 23 (8.0) 40 (13.5) 1.00 1.00
T/T Arg/Pro 18 (6.3) 38 (12.8) 0.85 (0.40–1.81) 0.51 (0.16–1.66)
T/T Pro/Pro 4 (1.4) 6 (2.0) 1.16 (0.30–4.54) 1.23 (0.15–10.10)
T/G Arg/Arg 48 (16.7) 56 (18.9) 1.49 (0.79–2.83) 1.57 (0.56–4.37)
T/G Arg/Pro 58 (20.2) 53 (17.9) 1.90 (1.01–3.59) 4.12 (1.45–11.68)
T/G Pro/Pro 19 (6.6) 23 (7.8) 1.44 (0.65–3.18) 3.94 (1.09–14.27)
G/G Arg/Arg 39 (13.6) 28 (9.5) 2.42 (1.20–4.91) 3.82 (1.27–11.49)
G/G Arg/Pro 35 (12.2) 45 (15.2) 1.35 (0.69–2.66) 2.15 (0.70–6.58)
G/G Pro/Pro 43 (15.0) 8 (2.7) 9.35 (3.75–23.28) 20.78 (5.25–82.36)
aAdjusted for all variables listed in Table I.
P , 0.05.
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HCC in patients with chronic hepatitis C infection. In this study, the
frequency of the G/G genotype was 34.0% (198/583), which was
much higher than that observed in Caucasians (12%) and slightly
higher than that observed in Japanese (27%) and Chinese (25%) sub-
jects in previous studies (19,20,32). These differences in genotype
frequency may be the result of differences in the study populations.
The G/G genotype was more frequent in HCC patients than in non-
HCC patients, which is consistent with the results of a previous report
by Dharel et al. (20). This report examined a larger study population
and demonstrated a clear association between MDM2 SNP 309 and
both HBV infection and the early onset of HCC.
The p53 tumor suppressor gene is critical for the regulation of the
cell cycle and the maintenance of cell integrity (13). The p53 gene is
polymorphic, with 13 described variants (37). The codon 72 poly-
morphism in exon 4 results in an arginine-to-proline substitution. This
polymorphism is located in a proline-rich region of the p53 protein,
which is required for growth suppression and apoptosis mediated by
p53. The association between p53 Arg72Pro and the risk of cancer has
been investigated in many organs, including the lung, esophagus,
stomach, breast, nasopharynx, prostate and liver (24–26,38–44).
However, these studies did not provide consistent results to support
the association between the p53 polymorphism and HCC; further-
more, Zhu et al. (25) reported that p53 Arg72Pro was not correlated
with HCC risk in patients with chronic HBV infection. However, this
study demonstrated that p53 Arg72Pro is associated with a risk of
HCC in HBV-infected patients; in particular, homozygosity for the
Pro allele of p53 was associated with an elevated risk of HCC.
The major etiological factors for HCC are infection with HBV or
HCV, excessive alcohol intake and aflatoxin B1 exposure (45–47).
However, the most important risk factor for the development of
HCC is cirrhosis, and other factors, such as age, gender and AFP,
are thought to contribute to the relative risk (10). Virus factors such
as HBV genotype, viral load and mutations in the BCP and/or PC
regions of HBV have been associated with HCC development (5,7–9).
Most of these factors were included for analysis in this study. Gender,
HBV DNA positive and mutations in PC 1896 were not different
between two groups. After multivariate analysis, heavy alcohol intake
and HBV genotype were not significant variables for HCC presence.
AFP 20 ng/ml was the most striking risk factor (OR 5 26.47,
95% CI 5 13.18–53.19). The sensitivity and specificity of AFP for
HCC detection at patient enrollment were 62.4 and 91.9%, respec-
tively, and these results were not much different from previous report
(48). As one would expect, age and cirrhosis were also strikingly
significant factors with an OR of 11.19 and 8.61, respectively. The
multivariate analysis demonstrated that the MDM2 G/G and p53
Pro/Pro genotypes caused 4.89- and 3.03-fold increased risk for HCC,
respectively.
Previous research has demonstrated an interaction between MDM2
and p53 at the molecular level (49), and the combined effects of
MDM2 SNP 309 and p53 Arg72Pro have been examined in lung
cancer, Li–Fraumeni syndrome and non-polyposis colorectal cancer,
with conflicting results (18,26,38). In this study, these two polymor-
phisms produced a combined effect on HCC risk in patients with
chronic HBV infection. MDM2 SNP 309 and p53 Arg72Pro were
not statistically independent, and the presence of both the G/G and
Arg/Arg genotypes resulted in a positive synergistic effect on the risk
of HCC, with an adjusted OR (95% CI) of 20.78 (5.25–82.36). The
presence of both T/G and Pro/Pro revealed significant risk of HCC
with an adjusted OR (95% CI) of 3.94 (1.09–14.27). Five combina-
tions (T/T and Pro/Pro, T/G and Arg/Arg, T/G and Arg/Pro, G/G and
Arg/Arg and G/G and Arg/Pro) had one genotype of significant risk
for HCC. The combination of T/T and Pro/Pro had small number of
patients and were not significant for HCC presence. The remaining
four combinations included MDM2 genotype of significant risk for
HCC presence and p53 genotype was not associated with HCC risk.
The two of these four combinations were associated with the presence
of HCC and the other two combinations were not.
In addition, analysis of variance with least significance difference
method was used to demonstrate that the MDM2 G/G and p53 Pro/Pro
genotypes were both associated with earlier age at HCC diagnosis.
However, previous reports have not tested or shown this result
(13,20,25). Subjects with G/G and Pro/Pro genotypes exhibited a sig-
nificant acceleration in the development of HCC compared with T/T
and Arg/Arg genotypes, respectively. The combination of both G/G
and Pro/Pro demonstrated further early onset of HCC compared with
combination of both T/T and Arg/Arg. Significant acceleration was
also noted in subjects with both G/G and Arg/Arg genotype.
This study has a number of limitations. The study design was cross-
sectional. Furthermore, since the study population was hospital based,
healthy subjects were not evaluated as a control group.
Despite these limitations, this study revealed an association of
MDM2 SNP 309 and/or p53 Arg72Pro with the risk of HCC. Further-
more, these polymorphisms were associated with an earlier age at
HCC diagnosis. These results suggest that MDM2 SNP 309 and p53
Arg72Pro are involved in HCC development and may be useful as
predictive markers of HCC in patients with chronic HBV infection.
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